BACKGROUND: Numerous economic models have assessed the cost-effectiveness of antipsychotic medications in schizophrenia. It is important to understand what key impacts of antipsychotic medications were considered in the existing models and limitations of existing models in order to inform the development of future models. OBJECTIVES: This systematic review aims to identify which clinical benefits, clinical harms, costs and cost savings of antipsychotic medication have been considered by existing models, to assess quality of existing models and to suggest good practice recommendations for future economic models of antipsychotic medications. METHODS: An electronic search was performed on multiple databases (MEDLINE, EMBASE, PsycInfo, Cochrane...
Introduction: Poor medication adherence among patients with schizophrenia is associated with a high ...
Background: In 2002, the National Institute for Health and Clinical Excellence (NICE), recommended a...
<p>INTRODUCTION: The prevalence of schizophrenia is thought to be about one in 100; about 75% ...
BACKGROUND: Numerous economic models have assessed the cost-effectiveness of antipsychotic medicatio...
BACKGROUND: Numerous economic models have assessed the cost-effectiveness of antipsychotic medicatio...
Background Numerous economic models have assessed the cost-effectiveness of antipsychotic medicat...
Background Numerous economic models have assessed the cost-effectiveness of antipsychotic medicat...
\ua9 2020, Springer Nature Switzerland AG.Background: Schizophrenia is associated with a high econom...
Background: Economic models are broadly used in the economic evaluation of antipsychotics in schizop...
Background: Schizophrenia is a severe and complex disease with substantial economic and social burde...
Background Schizophrenia is associated with a high economic burden. Economic models can help to inf...
INTRODUCTION: There is a growing need for economic evaluations describing the disease course, as wel...
Tatiana Dilla, Antonio Ciudad, María ÁlvarezDepartment of Clinical Research and Develo...
Wenjie Zhang,1 Tony B Amos,2 Stephen W Gutkin,1 Nicole Lodowski,1 Emma Giegerich,1 Kruti Joshi2 1WG ...
Introduction: Poor medication adherence among patients with schizophrenia is associated with a high ...
Introduction: Poor medication adherence among patients with schizophrenia is associated with a high ...
Background: In 2002, the National Institute for Health and Clinical Excellence (NICE), recommended a...
<p>INTRODUCTION: The prevalence of schizophrenia is thought to be about one in 100; about 75% ...
BACKGROUND: Numerous economic models have assessed the cost-effectiveness of antipsychotic medicatio...
BACKGROUND: Numerous economic models have assessed the cost-effectiveness of antipsychotic medicatio...
Background Numerous economic models have assessed the cost-effectiveness of antipsychotic medicat...
Background Numerous economic models have assessed the cost-effectiveness of antipsychotic medicat...
\ua9 2020, Springer Nature Switzerland AG.Background: Schizophrenia is associated with a high econom...
Background: Economic models are broadly used in the economic evaluation of antipsychotics in schizop...
Background: Schizophrenia is a severe and complex disease with substantial economic and social burde...
Background Schizophrenia is associated with a high economic burden. Economic models can help to inf...
INTRODUCTION: There is a growing need for economic evaluations describing the disease course, as wel...
Tatiana Dilla, Antonio Ciudad, María ÁlvarezDepartment of Clinical Research and Develo...
Wenjie Zhang,1 Tony B Amos,2 Stephen W Gutkin,1 Nicole Lodowski,1 Emma Giegerich,1 Kruti Joshi2 1WG ...
Introduction: Poor medication adherence among patients with schizophrenia is associated with a high ...
Introduction: Poor medication adherence among patients with schizophrenia is associated with a high ...
Background: In 2002, the National Institute for Health and Clinical Excellence (NICE), recommended a...
<p>INTRODUCTION: The prevalence of schizophrenia is thought to be about one in 100; about 75% ...